ESR1 and breast carcinoma: Thus, the concentrations of fulvestrant needed to inhibit mutant ERα activity may differ in the ER+ versus ER− cell line setting, and effective clinical exposures of fulvestrant to address mutant ERα may have been achieved in the FERGI study of ER+ breast cancer patients, although the data presented were an exploratory post hoc analysis.